HUE047394T2 - Nyújtott hatóanyagleadású, poloxamert tartalmazó gyógyászati készítmények - Google Patents
Nyújtott hatóanyagleadású, poloxamert tartalmazó gyógyászati készítményekInfo
- Publication number
- HUE047394T2 HUE047394T2 HUE09712268A HUE09712268A HUE047394T2 HU E047394 T2 HUE047394 T2 HU E047394T2 HU E09712268 A HUE09712268 A HU E09712268A HU E09712268 A HUE09712268 A HU E09712268A HU E047394 T2 HUE047394 T2 HU E047394T2
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical compositions
- sustained release
- containing pharmaceutical
- poloxamer containing
- release poloxamer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/90—Block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/594—Mixtures of polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/95—Involves in-situ formation or cross-linking of polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/036,139 US9107815B2 (en) | 2008-02-22 | 2008-02-22 | Sustained release poloxamer containing pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE047394T2 true HUE047394T2 (hu) | 2020-04-28 |
Family
ID=40640698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE09712268A HUE047394T2 (hu) | 2008-02-22 | 2009-02-11 | Nyújtott hatóanyagleadású, poloxamert tartalmazó gyógyászati készítmények |
Country Status (12)
Country | Link |
---|---|
US (4) | US9107815B2 (hu) |
EP (2) | EP2257304B1 (hu) |
KR (1) | KR101675168B1 (hu) |
CN (1) | CN102014951A (hu) |
AU (1) | AU2009215664B2 (hu) |
CA (1) | CA2715626C (hu) |
DK (1) | DK2257304T3 (hu) |
ES (1) | ES2759372T3 (hu) |
HU (1) | HUE047394T2 (hu) |
PL (1) | PL2257304T3 (hu) |
RU (1) | RU2482874C2 (hu) |
WO (1) | WO2009105369A1 (hu) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
DK3332805T3 (da) | 2008-12-31 | 2022-05-16 | Revance Therapeutics Inc | Injicerbare botulinumtoksinformuleringer |
BRPI1015938A2 (pt) * | 2009-06-25 | 2016-09-27 | Revance Therapeutics Inc | formulações da toxina botulínica livre de albumina |
WO2011053554A1 (en) * | 2009-10-30 | 2011-05-05 | Revance Therapeutics, Inc. | Device and method for topical application of therapeutics or cosmetic compositions |
EP2512507A4 (en) * | 2009-12-15 | 2013-04-17 | Ira Sanders | TREATMENT OF NOSE AND BREAST DRESS |
US8454975B1 (en) * | 2010-01-11 | 2013-06-04 | Elizabeth VanderVeer | Method for enhancing skin appearance |
DE212011100034U1 (de) | 2010-01-20 | 2012-07-04 | Theracoat Ltd. | Material zur Behandlung von inneren Hohlräumen |
US10471150B2 (en) * | 2010-01-20 | 2019-11-12 | Urogen Pharma Ltd. | Material and method for treating internal cavities |
JP2014510045A (ja) | 2011-02-08 | 2014-04-24 | ハロザイム インコーポレイテッド | ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用 |
WO2012131678A1 (en) | 2011-03-28 | 2012-10-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Sustained-release injectable formulation |
CA2841795C (en) | 2011-07-05 | 2020-09-15 | The Research Foundation For The State University Of New York | Compositions and methods for spinal disc repair and other surgical and non-surgical indications |
AU2015271940B2 (en) * | 2011-07-05 | 2018-02-08 | The Research Foundation For The State University Of New York | Compositions and methods for spinal disc repair and other surgical and non-surgical indications |
EP2836200B1 (en) * | 2012-04-08 | 2020-07-15 | Urogen Pharma Ltd. | Reverse thermal hydrogel preparations for use in the treatment of disorders of the urothelium |
US20140120077A1 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and Methods for Safe Treatment of Rhinitis |
US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
JP6738739B2 (ja) * | 2014-04-30 | 2020-08-12 | アラーガン、インコーポレイテッドAllergan,Incorporated | 膀胱内滴下注入用生物製剤 |
EP3747448A1 (en) | 2014-07-07 | 2020-12-09 | LifeRaft Biosciences, Inc. | A poloxamer composition free of long circulating material and methods for production and uses thereof |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
WO2016118040A1 (ru) * | 2015-01-21 | 2016-07-28 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Гель, содержащий нифедипин и лидокаина гидрохлорид, его применение и способ приготовления с использованием нанотехнологий |
RU2641570C2 (ru) * | 2015-01-21 | 2018-01-18 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Гель, включающий нифедипин и лидокаина гидрохлорид (варианты), применение геля, включающего нифедипин и лидокаина гидрохлорид (варианты), способ приготовления геля, включающего нифедипин и лидокаина гидрохлорид, с использованием нанотехнологии |
CN107206175B (zh) | 2015-02-03 | 2021-06-01 | 莫茨制药有限及两合公司 | 肉毒杆菌毒素预填充式容器 |
ITUB20155342A1 (it) * | 2015-11-06 | 2017-05-06 | Emenem Srl | Composizione di soluzioni-gel reversibili termosensibili mucoadesive a base di collagene e sali di acido ialuronico |
US20190183988A1 (en) * | 2016-05-27 | 2019-06-20 | Ipsen Biopharm Limited | Neurotoxin formulation |
KR102552356B1 (ko) | 2016-08-26 | 2023-07-07 | 에스케이 조인트 벤처스 | 보툴리눔 독소의 효능 증대를 위한 생분해성 폴리머 제제 |
KR20240023684A (ko) | 2016-09-13 | 2024-02-22 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
US20210162026A1 (en) | 2017-08-28 | 2021-06-03 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
EP3470054B1 (en) * | 2017-10-11 | 2023-09-20 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
WO2019126502A1 (en) | 2017-12-20 | 2019-06-27 | Allergan, Inc. | Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation |
EP3727334B1 (en) * | 2017-12-20 | 2023-06-07 | Alpha Strumenti S.r.l. | Pharmaceutical preparation comprising a topically released active ingredient and a heat-sensitive carrier, method of obtaining same, and use of same in the treatment of skin or mucosal infections |
US10607931B2 (en) | 2018-07-03 | 2020-03-31 | Texas Instruments Incorporated | Semiconductor device with electroplated die attach |
CA3111385A1 (en) | 2018-09-06 | 2020-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Sustained-release injectable antibiotical formulation |
US20200108129A1 (en) * | 2018-09-13 | 2020-04-09 | Allergan, Inc. | Clostridial toxin - hyaluronic acid compositions |
CN114269365A (zh) * | 2019-06-06 | 2022-04-01 | 埃克索运营公司 | 热凝胶化大麻素组合物及其制造和使用方法 |
WO2021113926A1 (en) * | 2019-12-13 | 2021-06-17 | Francesco Barbagallo | Botulinum toxin formulations and methods for intranasal delivery thereof for the treatment of allergic rhinitis |
KR102626199B1 (ko) * | 2021-07-01 | 2024-01-16 | 순천대학교 산학협력단 | 온도감응성 겔을 이용한 고체분산체의 조성 및 이의 제조방법 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5252318A (en) * | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
AU4646393A (en) | 1992-06-23 | 1994-01-24 | Interactive Biologics Associates | Pharmaceutical composition containing botulinum b complex |
DK0661989T3 (da) | 1992-09-21 | 1998-03-02 | Upjohn Co | Proteinsammensætninger med vedvarende frigivelse |
WO1994012158A1 (en) | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
US5516703A (en) * | 1993-08-20 | 1996-05-14 | The University Of Utah | Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands |
ZA954599B (en) * | 1994-06-07 | 1996-01-26 | Allergan Inc | Stable gel formulation for topical treatment of skin conditions |
US5756468A (en) | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
AU6034396A (en) | 1995-06-06 | 1996-12-24 | L. Bruce Pearce | Improved compositions and methods for chemodenervation using neurotoxins |
US6063405A (en) | 1995-09-29 | 2000-05-16 | L.A.M. Pharmaceuticals, Llc | Sustained release delivery system |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
CN1073626C (zh) | 1997-10-18 | 2001-10-24 | 卫生部兰州生物制品研究所 | A型肉毒结晶毒素的生产工艺及生产该毒素所需的冻干保护液 |
US6022554A (en) | 1997-12-15 | 2000-02-08 | American Home Products Corporation | Polymeric microporous film coated subcutaneous implant |
RU2123837C1 (ru) * | 1998-05-27 | 1998-12-27 | Бритун Юлия Анатольевна | Способ устранения морщин |
WO2000007603A2 (en) * | 1998-08-04 | 2000-02-17 | Madash Llp | End modified thermal responsive hydrogels |
US20120238504A1 (en) * | 1998-09-11 | 2012-09-20 | Solstice Neurosciences, Llc | Stable Formulations of Botulinum Toxin in Hydrogels |
TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
AU5154000A (en) * | 1999-05-19 | 2000-12-05 | Brigham Young University | Stabilization and acoustic activation of polymeric micelles for drug delivery |
DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
PT1398038E (pt) | 2000-02-08 | 2007-02-28 | Allergan Inc | Composições farmacêuticas de toxina botulínica |
US6465425B1 (en) * | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
US6773711B2 (en) * | 2000-02-15 | 2004-08-10 | Allergan, Inc. | Botulinum toxin therapy for Hashimoto's thyroiditis |
AU2001241958A1 (en) * | 2000-03-03 | 2001-09-17 | Valentis, Inc. | Improved poloxamer and poloxamine compositions for nucleic acid delivery |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US6565888B1 (en) * | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
EP1443907A1 (en) * | 2001-11-12 | 2004-08-11 | Alkermes Controlled Therapeutics, Inc. | Biocompatible polymer blends and uses thereof |
US7140371B2 (en) * | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
JP2006519761A (ja) | 2002-12-20 | 2006-08-31 | ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド | 改善された薬学的ボツリヌス毒素組成物 |
CN1446833A (zh) * | 2003-02-08 | 2003-10-08 | 复旦大学 | 一种温敏性可降解微凝胶及其制备方法 |
WO2004084839A2 (en) | 2003-03-24 | 2004-10-07 | Cady Roger K | Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
SE0300877D0 (sv) * | 2003-03-26 | 2003-03-26 | Sca Hygiene Prod Ab | Absorbent article comprising an absorbent structure |
EP1624859A4 (en) * | 2003-05-06 | 2010-06-23 | Bpsi Holdings Inc | METHOD FOR PRODUCING THERMOFORMED COMPOSITIONS WITH ACRYLIC POLYMER BINDERS, PHARMACEUTICAL DOSAGE FORMS, AND METHOD FOR THE PRODUCTION THEREOF |
US20050123550A1 (en) * | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
NL1023720C2 (nl) * | 2003-06-23 | 2004-12-28 | Univ Eindhoven Tech | Werkwijze voor het wijzigen van de transporteigenschappen van een materiaal, werkwijze voor het vrijmaken van een werkstof uit een implantaat, evenals implantaat met werkstof. |
AU2004253571A1 (en) * | 2003-07-02 | 2005-01-13 | Alza Corporation | Microprojection array immunization patch and method |
DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
US7160699B2 (en) * | 2003-09-25 | 2007-01-09 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
US8377951B2 (en) * | 2004-05-07 | 2013-02-19 | Phytotox Limited | Transdermal administration of phycotoxins |
KR100852822B1 (ko) | 2004-07-26 | 2008-08-18 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 신경독소를 포함하는 치료 조성물 |
WO2006020994A2 (en) * | 2004-08-13 | 2006-02-23 | Angiotech International Ag | Compositions and methods using hyaluronic acid and hyluronidase inhibitors |
US20060078616A1 (en) * | 2004-08-30 | 2006-04-13 | Georgewill Dawaye A | Thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol |
AU2005289520A1 (en) * | 2004-09-27 | 2006-04-06 | Vical Incorporated | Formulations and methods for treatment of inflammatory diseases |
WO2007001451A2 (en) * | 2004-11-09 | 2007-01-04 | Board Of Regents, The University Of Texas System | Stabilized hme composition with small drug particles |
US20060127429A1 (en) * | 2004-12-13 | 2006-06-15 | Mccartt Mary D | Topical numbing composition for laser therapy |
EP1861112A4 (en) * | 2005-03-03 | 2009-07-22 | Revance Therapeutics Inc | COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS |
DE102005011544A1 (de) * | 2005-03-10 | 2006-09-14 | Gkss-Forschungszentrum Geesthacht Gmbh | Verfahren zur Herstellung einer Polymermembran sowie Polymermembran |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US8168206B1 (en) * | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
US9486408B2 (en) * | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
DK1959994T3 (en) * | 2005-12-01 | 2017-12-04 | Univ Massachusetts Lowell | Botulinum nanoemulsions |
AU2007203715B2 (en) * | 2006-01-05 | 2012-08-02 | Veloxis Pharmaceuticals A/S | Disintegrating loadable tablets |
WO2007103555A2 (en) * | 2006-03-08 | 2007-09-13 | Nuviance, Inc. | Transdermal drug delivery compositions and topical compositions for application on the skin |
EP2010156B1 (en) * | 2006-03-24 | 2016-11-16 | Auxilium International Holdings, Inc. | Stabilized compositions containing alkaline labile drugs |
US20070253960A1 (en) * | 2006-04-28 | 2007-11-01 | Josee Roy | Pharmaceutical removal of vascular extensions from a degenerating disc |
US20080097229A1 (en) * | 2006-08-29 | 2008-04-24 | Josee Roy | Hygroscopic treatment for degenerating discs |
SG177184A1 (en) * | 2006-12-01 | 2012-01-30 | Anterios Inc | Amphiphilic entity nanoparticles |
WO2008120249A1 (en) * | 2007-03-30 | 2008-10-09 | Sifi S.P.A. | Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use |
US20090130048A1 (en) * | 2007-11-19 | 2009-05-21 | Oronsky Bryan Todd | Topical Composition for Treating Pain |
US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
US9044477B2 (en) * | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
CN101932707B (zh) * | 2008-01-31 | 2013-08-21 | 库瑞瓦格有限责任公司 | 作为免疫刺激剂/佐剂的式(I)(NuGlXmGnNv)a的核酸及其衍生物 |
US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
US20090258924A1 (en) * | 2008-04-15 | 2009-10-15 | Allergan, Inc. | METHODS, COMPOSITIONS AND DRUG DELIVERY SYSTEMS FOR INTRAOCULAR DELIVERY OF siRNA MOLECULES |
US9415006B2 (en) * | 2008-05-23 | 2016-08-16 | The Regents Of The University Of Michigan | Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same |
US20120156244A1 (en) * | 2008-08-01 | 2012-06-21 | Alpha Synergy Development Inc. | Nasal Compositions and Uses Thereof |
CN105833254A (zh) * | 2008-12-10 | 2016-08-10 | 阿勒根公司 | 梭菌毒素药物组合物 |
KR101233850B1 (ko) * | 2009-06-05 | 2013-02-15 | 서울대학교산학협력단 | 복합체, 이를 이용한 다층, 및 상기 다층이 코팅된 디바이스 |
WO2011053554A1 (en) * | 2009-10-30 | 2011-05-05 | Revance Therapeutics, Inc. | Device and method for topical application of therapeutics or cosmetic compositions |
DK2689774T3 (en) * | 2011-03-21 | 2019-04-01 | Broda Tech Co Ltd | REVERSE TERMOREVERSIBLE HYDROGEL COMPOSITIONS |
US8816591B2 (en) | 2012-05-26 | 2014-08-26 | Vastview Technology Inc. | Methods and apparatus for segmenting and driving LED-based lighting units |
CN104884064A (zh) * | 2012-12-24 | 2015-09-02 | 纽洛佳斯特拉斯公司 | 用于治疗胃肠道病症的方法 |
WO2016094617A1 (en) * | 2014-12-11 | 2016-06-16 | Phosphorex, Inc. | Aqueous topical drug formulation with controlled release and increased stability |
-
2008
- 2008-02-22 US US12/036,139 patent/US9107815B2/en active Active
-
2009
- 2009-02-11 HU HUE09712268A patent/HUE047394T2/hu unknown
- 2009-02-11 EP EP09712268.3A patent/EP2257304B1/en active Active
- 2009-02-11 CA CA2715626A patent/CA2715626C/en not_active Expired - Fee Related
- 2009-02-11 AU AU2009215664A patent/AU2009215664B2/en not_active Ceased
- 2009-02-11 EP EP19194887.6A patent/EP3632470A1/en not_active Withdrawn
- 2009-02-11 WO PCT/US2009/033752 patent/WO2009105369A1/en active Application Filing
- 2009-02-11 ES ES09712268T patent/ES2759372T3/es active Active
- 2009-02-11 DK DK09712268T patent/DK2257304T3/da active
- 2009-02-11 KR KR1020107020891A patent/KR101675168B1/ko active IP Right Grant
- 2009-02-11 RU RU2010138700/15A patent/RU2482874C2/ru active
- 2009-02-11 CN CN2009801140548A patent/CN102014951A/zh active Pending
- 2009-02-11 PL PL09712268T patent/PL2257304T3/pl unknown
-
2015
- 2015-08-17 US US14/827,665 patent/US9278140B2/en active Active
-
2016
- 2016-03-02 US US15/058,824 patent/US9981022B2/en active Active
-
2018
- 2018-05-25 US US15/989,742 patent/US20180271959A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2715626A1 (en) | 2009-08-27 |
EP2257304B1 (en) | 2019-09-04 |
PL2257304T3 (pl) | 2020-06-15 |
KR20100135237A (ko) | 2010-12-24 |
US9278140B2 (en) | 2016-03-08 |
RU2482874C2 (ru) | 2013-05-27 |
AU2009215664B2 (en) | 2014-07-03 |
US9981022B2 (en) | 2018-05-29 |
US20160175410A1 (en) | 2016-06-23 |
WO2009105369A1 (en) | 2009-08-27 |
EP3632470A1 (en) | 2020-04-08 |
US20180271959A1 (en) | 2018-09-27 |
DK2257304T3 (da) | 2019-12-02 |
AU2009215664A1 (en) | 2009-08-27 |
US9107815B2 (en) | 2015-08-18 |
US20090214685A1 (en) | 2009-08-27 |
CN102014951A (zh) | 2011-04-13 |
CA2715626C (en) | 2016-10-11 |
RU2010138700A (ru) | 2012-03-27 |
US20150352226A1 (en) | 2015-12-10 |
KR101675168B1 (ko) | 2016-11-10 |
ES2759372T3 (es) | 2020-05-08 |
EP2257304A1 (en) | 2010-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2257304T3 (pl) | Kompozycje farmaceutyczne o przedłużonym uwalnianiu zawierające poloksamer | |
HK1216232A1 (zh) | 控釋藥物組合物 | |
HK1164059A1 (en) | Compositions for drug administration | |
EP2240022A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
GB0814695D0 (en) | Pharmaceutical compositions | |
EP2373681A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
PL2323623T3 (pl) | Kompozycje farmaceutyczne | |
ZA201102715B (en) | Solid pharmaceutical composition | |
ZA201100635B (en) | Sustained release pharmaceutical compositions comprising quetiapine | |
EP2268278A4 (en) | PHARMACEUTICAL COMPOSITION | |
EP2306998A4 (en) | PHARMACEUTICAL FORMULATION | |
IL208788A (en) | Pharmacy-based formulation | |
ZA201100871B (en) | Solid pharmaceutical composition | |
IL207734A0 (en) | Pharmaceutical composition | |
IL206487A0 (en) | Pharmaceutical compositions | |
GB2464200B (en) | Pharmaceutical composition | |
GB0817969D0 (en) | Pharmaceutical composition | |
HK1182939A1 (en) | Stable pharmaceutical composition | |
GB0800659D0 (en) | Pharmaceutical Compositions | |
GB0813031D0 (en) | Pharmaceutical formulations | |
GB0810217D0 (en) | Pharmaceutical formulations | |
ZA201001127B (en) | Pharmaceutical formulation for extended release | |
IL178378A0 (en) | Extended release pharmaceutical compositions | |
HU0700172D0 (en) | Sustained release pharmaceutical preparation | |
GB0806156D0 (en) | Pharmaceutical compositions |